Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients
- 1 September 1998
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 23 (3) , 367-370
- https://doi.org/10.1007/bf03192295
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- THE EVOLUTION OF IMMUNOSUPPRESSION WITH FK506 IN PEDIATRIC LIVING-RELATED LIVER TRANSPLANTATION1Transplantation, 1996
- FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial.1995
- FK506 (TACROLIMUS) COMPARED WITH CYCLOSPORINE FOR PRIMARY IMMUNOSUPPRESSION AFTER PEDIATRIC LIVER TRANSPLANTATIONTransplantation, 1995
- Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patientsTransplant International, 1994
- DIFFERENCES IN ORAL FK506 DOSE REQUIREMENTS BETWEEN ADULT AND PEDIATRIC LIVER TRANSPLANT PATIENTSTransplantation, 1993
- Two-year experience with FK 506 in pediatric patients.1993
- FK 506 assay past and present--characteristics of FK 506 ELISA.1991
- FK 506 versus cyclosporine in pediatric liver transplantation.1991
- Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients.1991